FibroGen, Inc., a biopharmaceutical company, discovers, develops, and commercializes therapeutics to treat serious unmet medical needs. It is developing Roxadustat, an oral small molecule inhibitor of hypoxia inducible factor prolyl hydroxylases that is in Phase III clinical development for the treatment of anemia in chronic kidney disease in the United States and Europe; and in Phase II/III development in China for anemia associated with myelodysplastic syndromes. The company is also developing Pamrevlumab, a human monoclonal antibody that inhibits the activity of connective tissue growth factor that is in Phase III clinical development for the treatment of idiopathic pulmonary fibrosis, pancreatic cancer, liver fibrosis, and diabetic kidney disease, as well as Phase II trial for the treatment of Duchenne muscular dystrophy. It has collaboration agreements with Astellas Pharma Inc. and AstraZeneca AB. The company was incorporated in 1993 and is headquartered in San Francisco, California. |
Insider Trading |
Relationship |
Date |
Transaction |
Cost |
#Shares |
Value ($) |
#Shares Total |
SEC Form 4 |
Kurkijarvi Kalevi | Director | Feb 17 | Option Exercise | 28.65 | 6,000 | 171,900 | 39,100 | Feb 19 07:10 PM | Kurkijarvi Kalevi | Director | Feb 17 | Sale | 52.40 | 6,000 | 314,383 | 33,100 | Feb 19 07:10 PM | Kurkijarvi Kalevi | Director | Jan 19 | Option Exercise | 19.05 | 6,000 | 114,300 | 39,100 | Jan 21 07:24 PM | Kurkijarvi Kalevi | Director | Jan 19 | Sale | 43.38 | 6,000 | 260,280 | 33,100 | Jan 21 07:24 PM | Kurkijarvi Kalevi | Director | Jan 14 | Option Exercise | 19.05 | 5,999 | 114,281 | 39,099 | Jan 15 08:02 PM | Kurkijarvi Kalevi | Director | Jan 14 | Sale | 40.04 | 5,999 | 240,200 | 33,100 | Jan 15 08:02 PM | Schoeneck James A | Director | Jan 04 | Option Exercise | 9.78 | 6,000 | 58,650 | 15,400 | Jan 06 07:08 PM | Kurkijarvi Kalevi | Director | Dec 28 | Option Exercise | 18.34 | 6,001 | 110,059 | 39,101 | Dec 30 06:07 PM | Kurkijarvi Kalevi | Director | Dec 28 | Sale | 40.40 | 6,001 | 242,455 | 33,100 | Dec 30 06:07 PM | Yu K Peony | Chief Medical Officer | Dec 16 | Sale | 41.61 | 3,350 | 139,394 | 192,292 | Dec 17 07:06 PM | Cotroneo Pat | SVP, Finance and CFO | Dec 15 | Sale | 43.60 | 3,068 | 133,765 | 266,144 | Dec 17 07:04 PM | Kouchakji Elias | SVP, Clinical Dev, Drug Safety | Nov 17 | Option Exercise | 14.58 | 7,082 | 103,220 | 134,495 | Nov 19 04:52 PM | Yu K Peony | Chief Medical Officer | Sep 16 | Sale | 44.01 | 3,351 | 147,478 | 198,934 | Sep 18 05:19 PM | Cotroneo Pat | SVP, Finance and CFO | Sep 15 | Sale | 43.63 | 3,070 | 133,944 | 272,226 | Sep 17 06:03 PM | Yu K Peony | Chief Medical Officer | Sep 03 | Option Exercise | 18.00 | 10,000 | 180,000 | 215,576 | Sep 04 04:33 PM | Cotroneo Pat | SVP, Finance and CFO | Sep 03 | Option Exercise | 23.30 | 15,004 | 349,582 | 293,314 | Sep 04 04:30 PM | Yu K Peony | Chief Medical Officer | Sep 03 | Sale | 50.89 | 10,000 | 508,900 | 205,576 | Sep 04 04:33 PM | Cotroneo Pat | SVP, Finance and CFO | Sep 03 | Sale | 50.91 | 15,004 | 763,854 | 278,310 | Sep 04 04:30 PM | Schoeneck James A | Director | Aug 20 | Option Exercise | 5.95 | 6,000 | 35,700 | 15,400 | Aug 21 05:58 PM | Cotroneo Pat | SVP, Finance and CFO | Aug 11 | Option Exercise | 18.72 | 7,250 | 135,713 | 278,310 | Aug 11 04:34 PM | Cotroneo Pat | SVP, Finance and CFO | Aug 07 | Option Exercise | 19.39 | 22,554 | 437,322 | 293,614 | Aug 11 04:34 PM | Cotroneo Pat | SVP, Finance and CFO | Aug 07 | Sale | 48.00 | 22,554 | 1,082,592 | 271,060 | Aug 11 04:34 PM | Yu K Peony | Chief Medical Officer | Jul 24 | Sale | 42.35 | 3,351 | 141,915 | 205,576 | Jul 28 07:33 PM | Cotroneo Pat | SVP, Finance and CFO | Jun 16 | Sale | 39.68 | 3,928 | 155,863 | 271,060 | Jun 18 06:35 PM | Conterno Enrique A | Chief Executive Officer | Jun 11 | Buy | 35.28 | 19,800 | 698,599 | 27,800 | Jun 12 06:59 AM | Conterno Enrique A | Chief Executive Officer | Jun 10 | Buy | 36.29 | 8,000 | 290,282 | 8,000 | Jun 12 06:59 AM | Rosenkranz Roberto Pedro | Director | Jun 09 | Option Exercise | 23.85 | 24,000 | 572,400 | 96,100 | Jun 11 09:22 PM | Chung Christine | SVP, China Operations | Mar 19 | Option Exercise | 25.40 | 7,345 | 186,563 | 166,358 | Mar 19 07:55 PM | KEARNS THOMAS F JR | Director | Mar 19 | Option Exercise | 2.90 | 18,000 | 52,200 | 161,464 | Mar 23 05:37 PM | KEARNS THOMAS F JR | Director | Mar 19 | Sale | 23.17 | 18,000 | 417,074 | 143,464 | Mar 23 05:37 PM | Chung Christine | SVP, China Operations | Mar 19 | Sale | 25.91 | 7,345 | 190,282 | 159,013 | Mar 19 07:55 PM | Chung Christine | SVP, China Operations | Mar 18 | Option Exercise | 25.40 | 400 | 10,160 | 162,918 | Mar 19 07:55 PM | Chung Christine | SVP, China Operations | Mar 18 | Sale | 24.79 | 3,905 | 96,799 | 159,013 | Mar 19 07:55 PM | Yu K Peony | Chief Medical Officer | Mar 16 | Option Exercise | 19.39 | 3,750 | 72,713 | 166,541 | Mar 18 08:05 PM | Cotroneo Pat | SVP, Finance and CFO | Mar 16 | Sale | 26.36 | 9,239 | 243,540 | 236,466 | Mar 18 08:00 PM |
|